Compare Abbott Laboratories (ABT) vs Oklo Inc (OKLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Oklo Inc — how do they compare? Abbott Laboratories trades at $110.99 (market cap $187.95B), while Oklo Inc trades at $45.73 (market cap $8.74B). The key difference: Abbott Laboratories is far larger — about 21.5× Oklo Inc's market cap, and Abbott Laboratories pays a 2.32% dividend while Oklo Inc pays none. Which is the better fit depends on your goals.
| ABT | OKLO | |
|---|---|---|
Market Cap | $187.95B | $8.74B |
Sector | Health | Technology |
52-Week High | $136.62 | $174.14 |
52-Week Low | $82.57 | $36.84 |
Enterprise Value | $214.96B | $6.28B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
OKLO trades at $46.41, up 4.32% over 24 hours, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $77.07. The company reported its first revenue of $1.2 million in Q2 2026 but continues to post significant losses, with a net income margin of -12,625.54% in 2026. Recent milestones include achieving first criticality at its Groves isotope reactor, though cash burn remains high as it advances Aurora nuclear projects.
Outlook is speculative with high growth potential in nuclear energy infrastructure, but risks include persistent losses, execution challenges, and reliance on financing. Analyst sentiment is strongly bullish (76.9% buy ratings), yet investors must weigh the long-term payoff against near-term financial instability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Oklo Inc
Oklo Inc. is a company focused on developing and commercializing advanced fission power plants. The company specializes in micro-reactor technology, specifically the Aurora design, which uses advanced fuel to produce reliable, clean, and cost-competitive power. Oklo aims to provide scalable, on-site power solutions to various customers, including remote communities, industrial facilities, and government entities, positioning itself as an innovator in the next generation of nuclear energy.
Read more on OKLO →
